Aiforia Technologies (AIFORIA) Q2 2024 earnings summary

Executive summary

• Achieved 43% year-over-year revenue growth to EUR 1,372 thousand, driven by major clinical wins, new strategic partnerships, and expanded global presence, including a licensing agreement with Mayo Clinic.

• Secured multi-year and framework contracts with major health authorities in Europe and the US, including Fimlab, Mayo Clinic, and regional health authorities.

• Expanded preclinical offerings with new AI models and launched a GLP-compliant software module for non-clinical studies.

• Raised EUR 9.95 million via a directed share issue to institutional and qualified investors to support growth and R&D.

• Order book increased 34% to EUR 3,235 thousand, reflecting strong demand and backlog growth.

Financial highlights

• Revenue grew 43% year-over-year to EUR 1,372 thousand for H1 2024, mainly from clinical segment growth in Europe.

• EBITDA improved to EUR -4,198 thousand from EUR -4,971 thousand year-over-year.

• EBIT was EUR -6,073 thousand, and net loss narrowed to EUR -5,966 thousand.

• Cash and financial assets at period end were EUR 17,923 thousand.

• Fixed costs decreased 7% year-over-year to EUR 7.8 million, with operating cash flow improving by EUR 800,000 to EUR -3.8 million.

Outlook and guidance

• Short-term targets (2024–2025) include expanding AI offerings, forming at least three new strategic partnerships, achieving 15 key accounts, and reaching positive operating cash flow.

• Mid-term goals by 2030 are to cover 80% of the pathologist's workflow, achieve profitability by 2027, and surpass EUR 100 million in revenue.

• U.S. growth constrained by regulatory hurdles, but expected to accelerate with new FDA frameworks and reimbursement practices.

• Focused on scaling delivery, upselling existing customers, and expanding key accounts.